News
Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...
A new trial has found that a weight loss drug taken monthly helps people to lose 20 percent of their body weight. Other weight loss medications such as Ozempic, Wegovy and Mounjaro have become popular ...
In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...
While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...
Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...
The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...
Obesity late-comer Amgen announced full results from Part 1 of the Phase II study of MariTide (maridebart cafraglutide, ...
A new experimental drug meant to be taken just once a month could lead to “substantial weight reduction” within a year and ...
A new trial has found that a weight loss drug taken monthly helps people lose 20 percent of their body weight. Weight loss ...
Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...
Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results